NAV

Fotemustine

Identification

Summary

Fotemustine is an alkylating agent used in the treatment of metastatic melanoma.

Generic Name
Fotemustine
DrugBank Accession Number
DB04106
Background

Not Available

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 315.691
Monoisotopic: 315.075084952
Chemical Formula
C9H19ClN3O5P
Synonyms
  • (+-)-Diethyl (1-(3-(2-chloroethyl)-3-nitrosoureido)ethyl)phosphonate
  • Diethyl-1-(3-(2-chloroethyl)-3-nitrosoureido)ethylphosphonate
  • Fotemustina
  • Fotemustine
  • Fotemustinum
  • Mustoforan
External IDs
  • S 10036
  • S-10036
  • Servier-10036
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofMetastatic melanoma••••••••••••••••••• ••• ••••••••• ••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UThioredoxin reductase 1, cytoplasmicNot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AmbroxolThe risk or severity of methemoglobinemia can be increased when Fotemustine is combined with Ambroxol.
ArticaineThe risk or severity of methemoglobinemia can be increased when Fotemustine is combined with Articaine.
BenzocaineThe risk or severity of methemoglobinemia can be increased when Fotemustine is combined with Benzocaine.
Benzyl alcoholThe risk or severity of methemoglobinemia can be increased when Fotemustine is combined with Benzyl alcohol.
BupivacaineThe risk or severity of methemoglobinemia can be increased when Fotemustine is combined with Bupivacaine.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

ATC Codes
L01AD05 — Fotemustine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as dialkyl alkylphosphonates. These are compounds containing a phosphonic acid that is diesterified with alkyl groups, and the phosphorus atom is also directly attached to an alkyl group.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Organic phosphonic acids and derivatives
Sub Class
Phosphonic acid diesters
Direct Parent
Dialkyl alkylphosphonates
Alternative Parents
Phosphonic acid esters / Nitrosoureas / Semicarbazides / Nitrosamides / Organopnictogen compounds / Organophosphorus compounds / Organochlorides / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
show 1 more
Substituents
Aliphatic acyclic compound / Alkyl chloride / Alkyl halide / Carbonic acid derivative / Carbonyl group / Dialkyl alkylphosphonate / Hydrocarbon derivative / Nitrosamide / Nitrosourea / Organic n-nitroso compound
show 12 more
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
GQ7JL9P5I2
CAS number
92118-27-9
InChI Key
YAKWPXVTIGTRJH-QMMMGPOBSA-N
InChI
InChI=1S/C9H19ClN3O5P/c1-4-17-19(16,18-5-2)8(3)11-9(14)13(12-15)7-6-10/h8H,4-7H2,1-3H3,(H,11,14)/t8-/m0/s1
IUPAC Name
diethyl [(1S)-1-{[N-(2-chloroethyl)-N'-oxohydrazinecarbonyl]amino}ethyl]phosphonate
SMILES
CCOP(=O)(OCC)[C@@H](C)NC(=O)N(CCCl)N=O

References

Synthesis Reference
US4567169
General References
Not Available
PubChem Compound
46936889
PubChem Substance
46505097
ChemSpider
26330202
ChEBI
131854
ZINC
ZINC000005859934
Wikipedia
Fotemustine

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
3CompletedTreatmentMalignant Melanoma / Recurrent Melanoma1
3TerminatedTreatmentIntraocular Melanoma / Metastatic Cancer1
3Unknown StatusTreatmentBrain Metastases1
2CompletedTreatmentGlioblastoma Multiforme (GBM)1
2CompletedTreatmentMalignant Melanoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Powder, for solutionIntravenous208 MG
Injection, powder, for solutionIntravenous200 mg/4ml
SolutionIntravenous208 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility4.11 mg/mLALOGPS
logP1.23ALOGPS
logP1.28Chemaxon
logS-1.9ALOGPS
pKa (Strongest Acidic)11.81Chemaxon
pKa (Strongest Basic)-5.4Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area97.3 Å2Chemaxon
Rotatable Bond Count9Chemaxon
Refractivity71.42 m3·mol-1Chemaxon
Polarizability29 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9709
Blood Brain Barrier+0.7425
Caco-2 permeable-0.5823
P-glycoprotein substrateNon-substrate0.6191
P-glycoprotein inhibitor INon-inhibitor0.6195
P-glycoprotein inhibitor IINon-inhibitor0.755
Renal organic cation transporterNon-inhibitor0.8932
CYP450 2C9 substrateNon-substrate0.7887
CYP450 2D6 substrateNon-substrate0.8071
CYP450 3A4 substrateNon-substrate0.5117
CYP450 1A2 substrateNon-inhibitor0.7836
CYP450 2C9 inhibitorNon-inhibitor0.7355
CYP450 2D6 inhibitorNon-inhibitor0.8882
CYP450 2C19 inhibitorNon-inhibitor0.67
CYP450 3A4 inhibitorNon-inhibitor0.8724
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8853
Ames testAMES toxic0.9107
CarcinogenicityCarcinogens 0.7102
BiodegradationNot ready biodegradable0.8846
Rat acute toxicity3.1868 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6413
hERG inhibition (predictor II)Non-inhibitor0.8627
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0pb9-5590000000-18944c7128f74192be3f
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0390000000-e45f8846e5ec1adb7ec9
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00dr-1091000000-758bca253eca5b1c624f
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-0490000000-f9e7fa2a2d150f7ba2ba
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-7910000000-f581d34c916677cf0e0d
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0900-4910000000-65f7481584631d703448
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-7930000000-3ea904693334ffa3b7b0
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-164.25882
predicted
DeepCCS 1.0 (2019)
[M+H]+166.61682
predicted
DeepCCS 1.0 (2019)
[M+Na]+172.70995
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Thioredoxin reductase 1, cytoplasmic
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Thioredoxin-disulfide reductase activity
Specific Function
Isoform 1 may possess glutaredoxin activity as well as thioredoxin reductase activity and induces actin and tubulin polymerization, leading to formation of cell membrane protrusions. Isoform 4 enha...
Gene Name
TXNRD1
Uniprot ID
Q16881
Uniprot Name
Thioredoxin reductase 1, cytoplasmic
Molecular Weight
70905.58 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 09, 2021 08:40